HealthyDirect · GrowthFit for a long SIP
ICICI Prudential Nifty Pharma Index Fund
ICICI Prudential Mutual FundOther Scheme - Index Funds3.9 years
- NAV
- 20.9974
- 30 Oct 2026
- 1Y
- +21.8%
- Trailing CAGR
- AUM
- ₹163.1 Cr
- 30 Sept 2026
- Volatility
- Medium
- 14.5% annualized
Buying brief
Should you add this fund?
Evidence on this desk, framed as a purchase checklist - not SEBI-registered advice.
As of 30 Oct 2026
Stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
In three lines
Fits if · The fund beat the category median in 100% of rolling 3-year windows.
Fits if · Three-year return is above the category median.
Buy checklist
History depth
Watch
3.9 years - usable, still building a track record.
Engine status
Pass
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Expense ratio
Pass
0.51% TER (Direct). Lower cost compounds on long SIPs.
Drawdown vs peers
Pass
Peak-to-trough -16.6%. Ask whether you can hold through a similar fall.
Vs category
Pass
100% of rolling 3Y windows beat the category median, same plan and option.
Manager tenure
n/a
Manager not listed.
Exit load
n/a
No exit-load summary on file.
Tax / wrapper
Pass
Direct Growth, no ELSS lock flagged. Equity LTCG rules still apply after one year - not tax advice.
Portfolio concentration
Watch
Top 10 holdings ≈ 78.1% of the portfolio.
Evidence supports a shortlist - confirm with peers before you buy elsewhere.
Before you buy or SIP
Behaviour and wrappers - the usual India MF failure modes - not a buy instruction.
Drawdown rehearsal
This scheme’s worst fall on file is about 17%. Before you SIP, ask whether you would keep contributing through a similar drop - pausing on fear is the usual India MF failure mode.
SIP discipline
If you start a SIP here, diary a 90-day check and an annual review - don’t react to every NAV print.
NAV
Path not in current snapshots
n/a
Returns
Trailing CAGR and simulated monthly SIP XIRR from daily NAV. Category comparison uses the median of comparable share classes in the peer set.
Trailing CAGR
Point-to-point, calendar-day annualized
- 1Y+21.8%
- 3Y+22.5%
- 5Yn/a
- 10Yn/a
- SI+21.3%
SIP XIRR
Equal monthly instalments to latest NAV
- 1Y+27.2%
- 3Y+16.7%
- 5Yn/a
- 10Yn/a
- Since inception
- +21.3%
- Calendar-day CAGR
- Excess 1Y
- +24.3%
- Category median, same plan and option
- 3Y win rate
- +100%
- Windows beating the median
- 3Y percentile
- 97
- Vs comparable share classes
- SIP 3Y XIRR
- +16.7%
- Simulated monthly SIP
- Worst rolling 3Y
- +18.8%
- 217 daily-ending windows
- Median rolling 3Y
- +21.7%
- Calendar-day CAGR
- Positive rolling 5Y
- n/a
- 0 daily-ending windows
Drawdown
Peak to trough from a running NAV high, with the path and recovery episodes.
- Max drawdown
- -16.6%
- Worst peak-to-trough
- Current
- -0.3%
- Below last peak
- Current spell
- 60 days
- Days below latest peak
- Time below peak
- +87%
- NAV observations
Drawdown
Path not in current snapshots
n/a
- Average recovery
- 14 days
- 54 recovered episodes
- Longest recovery
- 432 days
- Trough to prior peak
9 Oct 2024 – 6 May 2026
Trough 28 Feb 2025 · recovered in 432 days
-16.6%
21 Dec 2022 – 6 Jun 2023
Trough 13 Mar 2023 · recovered in 85 days
-10.0%
31 Aug 2026 – open
Trough 23 Oct 2026 · not recovered
-6.9%
9 Aug 2023 – 17 Nov 2023
Trough 26 Oct 2023 · recovered in 22 days
-6.8%
Dimensions
0–100 reads of named metrics. The mean is unweighted and only uses dimensions with data.
Returns
97
Vs category
100
Consistency
90
Risk-adjusted
76
Drawdown
59
Mean
84
Decision
Quantitative engine reasons behind the buying stance. An explanation can only restate what is already here.
Healthy
Buying stance
Fit for a long SIP
Evidence supports keeping this on a shortlist for a multi-year equity SIP.
Why this status
- No material deterioration, cost shock, or persistent category underperformance in the current evidence set.
Supporting reads
- The fund beat the category median in 100% of rolling 3-year windows.
- Three-year return is above the category median.
- Risk-adjusted return sits above the documented risk-free proxy.
Portfolio
30 Sept 2026 · 21 holdings · top 10 are 78.1%.
- Top 5
- 54.6%
- Top 10
- 78.1%
- Largest holding
- 19.5%
- Effective holdings
- 11.4
Sun Pharmaceutical Industries Ltd
Healthcare
19.5%
Divi's Laboratories Ltd
Healthcare
12.0%
Laurus Labs Ltd
Healthcare
7.8%
Cipla Ltd
Healthcare
7.7%
Dr. Reddy's Laboratories Ltd
Healthcare
7.6%
Worth investigating
Same-category peers with enough history to inspect beside this fund - including tradeoffs.
Aditya Birla Sun Life Nifty SDL Apr 2027 Index Fund
Aditya Birla Sun Life Mutual Fund
- 1Y
- +5.6%
- 3Y
- +7.4%
- Vol
- 1.4%
- Max DD
- -3.5%
- Sharpe
- 0.36
- 3Y win
- +0%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
Axis CRISIL IBX 50:50 Gilt Plus SDL June 2028 Index Fund
Axis Mutual Fund
- 1Y
- +4.6%
- 3Y
- +7.4%
- Vol
- 1.2%
- Max DD
- -0.8%
- Sharpe
- 1.08
- 3Y win
- +1%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
Bajaj Finserv Nifty 50 Index Fund
Bajaj Finserv Mutual Fund
- 1Y
- -10.5%
- 3Y
- n/a
- Vol
- 12.4%
- Max DD
- -14.9%
- Sharpe
- -0.80
- 3Y win
- n/a
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
BANDHAN CRISIL IBX GILT APRIL 2026 INDEX FUND
Bandhan Mutual Fund
- 1Y
- +5.8%
- 3Y
- +6.8%
- Vol
- 0.8%
- Max DD
- -0.4%
- Sharpe
- 1.62
- 3Y win
- 0%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns
DSP Nifty SDL Plus G-Sec Sep 2027 50:50 Index Fund
DSP Mutual Fund
- 1Y
- +5.1%
- 3Y
- +7.5%
- Vol
- 0.9%
- Max DD
- -0.3%
- Sharpe
- 1.54
- 3Y win
- +6%
- Lower volatility
- Shallower drawdown
- Lower TER
Caveat: Lower trailing returns